Pembrolizumab plus ipilimumab following anti-PD-1/L1 failure in melanoma
Source: MDLinx, May 2021
Researchers present findings of the first prospective clinical trial assessing ipilimumab 1mg/kg plus pembrolizumab for melanoma following progressed on anti-PD-1 (programmed cell death protein-1) immunotherapy.
